Lucid Diagnostics (LUCD)
(Delayed Data from NSDQ)
$0.82 USD
-0.03 (-3.31%)
Updated Aug 23, 2024 03:59 PM ET
After-Market: $0.80 -0.02 (-2.32%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth A Momentum D VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
LUCD 0.82 -0.03(-3.31%)
Will LUCD be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for LUCD based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for LUCD
Lucid Diagnostics (LUCD) Reports Positive ESOGUARD BE-1 Data
LUCD: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for LUCD
Lucid Diagnostics Announces Publication of Analytical Validation Study of EsoGuard? for Early Detection of Esophageal Precancer and Cancer
The American Foregut Society Formally Requests Medical Policy Coverage of EsoGuard? to Enhance Early Detection of Esophageal Cancer
PAVmed Provides Business Update and Second Quarter 2024 Financial Results
Lucid Diagnostics: Strong Buy Rating on Rising Test Volume and Promising Coverage Prospects
Buy Rating Affirmed for Lucid Diagnostics Amidst Growth and Strategic Advances